Literature DB >> 24192818

Maintaining normal levels of ionized calcium during citrate-based renal replacement therapy is associated with stable parathyroid hormone levels.

Mário Raimundo1, Siobhan Crichton, Katie Lei, Barnaby Sanderson, John Smith, John Brooks, Josephine Ng, Joanna Lemmich Smith, Catherine McKenzie, Richard Beale, Helen Dickie, Marlies Ostermann.   

Abstract

BACKGROUND/AIMS: Citrate is an effective anticoagulant during continuous renal replacement therapy (CRRT). Previous studies showed raised parathyroid hormone (PTH) levels when aiming for serum ionized calcium [Cai] between 0.8 and 1.1 mmol/l. Our objective was to assess whether citrate-based CRRT with physiologic target systemic [Ca(i)] between 1.12 and 1.20 mmol/l could maintain stable PTH levels.
METHODS: Measurement of intact PTH (PTHi) in 30 consecutive critically ill patients treated with citrate-based CRRT.
RESULTS: Thirty patients [mean age: 70.4 (SD 11.3) years; 56.7% males] were enrolled. Mean serum [Ca(i)] was 1.16 mmol/l (SD 0.09), 1.13 mmol/l (SD 0.09), 1.17 mmol/l (SD 0.05) and 1.16 mmol/l (SD 0.04) at baseline, 12, 24 and 48 h, respectively (p = 0.29). Median PTHi levels (interquartile range) at baseline, 12, 24 and 48 h were 66.5 (43-111), 109 (59.5-151.5), 88.5 (47-133) and 85 pg/ml (53-140), respectively. The differences between baseline and 12 h and across all time points were statistically not significant (p = 0.16 and p = 0.49, respectively). In a mixed-effects model, each 0.1 mmol/l increase in serum [Ca(i)] was associated with a 31.2% decrease in PTHi (p < 0.001). Results were unchanged after adjustment for age, gender, magnesium, phosphate, arterial pH and time spent on CRRT.
CONCLUSIONS: Maintaining systemic [Ca(i)] within the physiologic range was associated with stable PTHi levels.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24192818     DOI: 10.1159/000355860

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  4 in total

Review 1.  [Citrate anticoagulation in acute renal replacement therapy : Method of choice].

Authors:  R D Frank
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-05-22       Impact factor: 0.840

Review 2.  [Regional citrate anticoagulation in renal replacement therapy in the intensive care station : Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI].

Authors:  M Schmitz; M Joannidis; D Czock; S John; A Jörres; S J Klein; M Oppert; V Schwenger; J Kielstein; A Zarbock; D Kindgen-Milles; C Willam
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-05-08       Impact factor: 0.840

Review 3.  Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury.

Authors:  Sean M Bagshaw; Michael Darmon; Marlies Ostermann; Fredric O Finkelstein; Ron Wald; Ashita J Tolwani; Stuart L Goldstein; David J Gattas; Shigehiko Uchino; Eric A Hoste; Stephane Gaudry
Journal:  Intensive Care Med       Date:  2017-03-13       Impact factor: 17.440

4.  Citrate dose for continuous hemofiltration: effect on calcium and magnesium balance, parathormone and vitamin D status, a randomized controlled trial.

Authors:  Willem Boer; Tom Fivez; Margot Vander Laenen; Liesbeth Bruckers; Hans Jurgen Grön; Miet Schetz; Heleen Oudemans-van Straaten
Journal:  BMC Nephrol       Date:  2021-12-11       Impact factor: 2.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.